AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12593498 — intervention group
Group type: COMPARATOR
Intervention: Unstable angina pectoris (UAP)
Number of subjects: 59
Study 12593498 — intervention group
Group type: COMPARATOR
Intervention: Stable angina pectoris (SAP)
Number of subjects: 59
Study 12593498 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy controls
Number of subjects: 59
Study 10510219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (221 +/- 18 mg; range 60-360 mg)
Number of subjects: 60
Study 10510219 — intervention group
Group type: COMPARATOR
Intervention: Oral alendronate 40 mg daily
Number of subjects: 60
Study 10510219 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pamidronate 60 mg every 3 months
Number of subjects: 60
Study 8725987 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.2 mg/kg)
Number of subjects: 60
Study 8725987 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg)
Number of subjects: 60
Study 8725987 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 60
Study 1763596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.7 mg/kg BW i.v. before anaesthesia, and 0.35 mg/kg BW 15 and 30 min after the first dose
Number of subjects: 30
Study 1763596 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1.5 mg/kg BW i.v. before anaesthesia
Number of subjects: 30
Study 7157926 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase 500,000 IU within 30 min
Number of subjects: 93
Study 7157926 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase 1,500,000 IU within 60 min
Number of subjects: 93
Study 7157926 — intervention group
Group type: COMPARATOR
Intervention: Control group (no streptokinase treatment)
Number of subjects: 93
Study 31796519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 21 days and Vorinostat 400 mg orally 5 days on and 2 days off during each 21-day cycle
Number of subjects: 50
Study 31796519 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) in all patients
Number of subjects: 50
Study 30936281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 0
Study 30936281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28983665 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic vaginal gel (5 mg) plus three 250 mg metronidazole tablets per day for 7 days
Number of subjects: 100
Study 28983665 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole tablet alone (three 250 mg tablets per day for 7 days)
Number of subjects: 100
Study 27029815 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 106
Study 27029815 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study 24475766 — intervention group
Group type: EXPERIMENTAL
Intervention: Self Determination Theory-based exercise referral intervention
Number of subjects: 347
Study 24475766 — intervention group
Group type: COMPARATOR
Intervention: Standard provision exercise referral
Number of subjects: 347
Study 24475766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (SDT and standard provision)
Number of subjects: 347
Study 22748465 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-21 concentration at baseline (mean 46 h)
Number of subjects: 100
Study 22748465 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-21 concentration at 24 weeks
Number of subjects: 100
Study 22748465 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-21 correlation with ΔLVESVI
Number of subjects: 100
Study 22748465 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-21 correlation with change in LV end-diastolic volume index
Number of subjects: 100
Study 22748465 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-21 as an independent predictor of remodelling
Number of subjects: 100
Study 20495510 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Tac with daclizumab induction
Number of subjects: 199
Study 20495510 — intervention group
Group type: COMPARATOR
Intervention: Standard Tac
Number of subjects: 199
Study 18041436 — intervention group
Group type: COMPARATOR
Intervention: Glucomannan (1 g) before 75-g glucose load
Number of subjects: 20
Study 18041436 — intervention group
Group type: COMPARATOR
Intervention: Glucomannan (3 g/day for 4 weeks)
Number of subjects: 20
Study 18041436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16118723 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin suppository
Number of subjects: 0
Study 11509289 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted system (Group V)
Number of subjects: 60
Study 11509289 — intervention group
Group type: COMPARATOR
Intervention: Siphon-dependent system (Group S)
Number of subjects: 60
Study 9755295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (200 mg IV)
Number of subjects: 24
Study 9755295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg IV)
Number of subjects: 24
Study 7823260 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg aspirin (ASA) administered daily for two weeks
Number of subjects: 21
Study 7823260 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-pregnant subjects)
Number of subjects: 21
Study 3392236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of loprazolam
Number of subjects: 16
Study 3392236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of loprazolam
Number of subjects: 16
Study 30298608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (ART at study enrollment)
Number of subjects: 4580
Study 30298608 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (ART when CD4 count fell below 350 cells/µL)
Number of subjects: 4580
Study 27838831 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic total extraperitoneal repair (TEP)
Number of subjects: 60
Study 27838831 — intervention group
Group type: COMPARATOR
Intervention: Open Lichtenstein repair
Number of subjects: 60
Study 25760804 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg once daily)
Number of subjects: 221
Study 25760804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 25760804 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and Placebo (combined)
Number of subjects: 221
Study 25045726 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of vitamin E + selenium 3 weeks prepartum
Number of subjects: 60
Study 25045726 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of oral vitamin E from 3 weeks prepartum to parturition
Number of subjects: 60
Study 25045726 — intervention group
Group type: EXPERIMENTAL
Intervention: Injective vitamin E + selenium with daily supplementation of oral vitamin E
Number of subjects: 60
Study 21849399 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with metabolic syndrome
Number of subjects: 462
Study 21849399 — intervention group
Group type: COMPARATOR
Intervention: Patients without metabolic syndrome
Number of subjects: 462
Study 19318111 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet (30/40/30% of energy of protein/carbohydrate/fat)
Number of subjects: 10
Study 19318111 — intervention group
Group type: COMPARATOR
Intervention: Adequate Protein (AP) diet (10/60/30% of energy of protein/carbohydrate/fat)
Number of subjects: 10
Study 17653531 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise for 10 minutes
Number of subjects: 45
Study 17653531 — intervention group
Group type: COMPARATOR
Intervention: Positive expectation manipulation
Number of subjects: 45
Study 17653531 — intervention group
Group type: COMPARATOR
Intervention: Negative expectation manipulation
Number of subjects: 45
Study 17653531 — intervention group
Group type: COMPARATOR
Intervention: Neutral expectation manipulation
Number of subjects: 45
Study 15310772 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention (SDMI)
Number of subjects: 88
Study 15310772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 11522161 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief proactive educational intervention over the telephone with two follow-up mailouts
Number of subjects: 1717
Study 9131946 — intervention group
Group type: EXPERIMENTAL
Intervention: S-flurbiprofen (75 mg)
Number of subjects: 11
Study 9131946 — intervention group
Group type: EXPERIMENTAL
Intervention: R-flurbiprofen (75 mg)
Number of subjects: 11
Study 9131946 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 11
Study 8395177 — intervention group
Group type: EXPERIMENTAL
Intervention: Parodontax dentifrice
Number of subjects: 128
Study 8395177 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate placebo dentifrice
Number of subjects: 128
Study 3526824 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (running)
Number of subjects: 60
Study 3526824 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 60
Study 3526824 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 60
Study 28993177 — intervention group
Group type: EXPERIMENTAL
Intervention: DKK1 at T1 (CR)
Number of subjects: 69
Study 28993177 — intervention group
Group type: EXPERIMENTAL
Intervention: DKK1 at T2 (4 months before relapse)
Number of subjects: 69
Study 28993177 — intervention group
Group type: EXPERIMENTAL
Intervention: DKK1 at T3 (relapse)
Number of subjects: 69
Study 28993177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerostin at T1 (CR)
Number of subjects: 69
Study 28993177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerostin at T2 (4 months before relapse)
Number of subjects: 69
Study 28993177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerostin at T3 (relapse)
Number of subjects: 69
Study 28993177 — intervention group
Group type: EXPERIMENTAL
Intervention: P1NP at T1 (CR)
Number of subjects: 69
Study 28993177 — intervention group
Group type: EXPERIMENTAL
Intervention: P1NP at T2 (4 months before relapse)
Number of subjects: 69
Study 28993177 — intervention group
Group type: EXPERIMENTAL
Intervention: P1NP at T3 (relapse)
Number of subjects: 69
Study 27077337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with CHW-led sessions
Number of subjects: 203
Study 27077337 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study 25547003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal raltitrexed in normal saline (500 ml)
Number of subjects: 91
Study 25547003 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (500 ml)
Number of subjects: 91
Study 22925840 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Aspiration (MA)
Number of subjects: 56
Study 22925840 — intervention group
Group type: COMPARATOR
Intervention: Conventional Chest Tube Drainage (TT)
Number of subjects: 56
Study 20818903 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel (600 mg loading dose on day 1, followed by 150 mg daily for 6 days and 75 mg daily thereafter)
Number of subjects: 25086
Study 20818903 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (300 mg loading dose and 75 mg daily thereafter)
Number of subjects: 25086
Study 20818903 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel
Number of subjects: 25086
Study 20818903 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel
Number of subjects: 25086
Study 20818903 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose aspirin (300 to 325 mg daily)
Number of subjects: 25086
Study 20818903 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose aspirin (75 to 100 mg daily)
Number of subjects: 25086
Study 20818903 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose aspirin
Number of subjects: 25086
Study 20818903 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose aspirin
Number of subjects: 25086
Study 18268067 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 15
Study 18268067 — intervention group
Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 15
Study 15778953 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadodiamide
Number of subjects: 30
Study 15778953 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadodiamide
Number of subjects: 30
Study 12663712 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (MACOP-B regimen)
Number of subjects: 150
Study 12663712 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (HDT-ASCT)
Number of subjects: 150
Study 10362762 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (M) and Women (W) matched by VO2 max (46.1 +/- 2.0 and 43.6 +/- 2.9 ml. kg‐1. min‐1)
Number of subjects: 25
Study 10362762 — intervention group
Group type: COMPARATOR
Intervention: Men (MF) with higher fitness level (VO2 max of 59.1 +/- 1.8 ml. kg‐1. min‐1)
Number of subjects: 25
Study 8895239 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PSW
Number of subjects: 92
Study 8895239 — intervention group
Group type: COMPARATOR
Intervention: Placebo PSW
Number of subjects: 92
Study 8895239 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 92
Study 8315433 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (BU) and cyclophosphamide (CY) with total-body irradiation (TBI)
Number of subjects: 47
Study 8315433 — intervention group
Group type: COMPARATOR
Intervention: Busulfan (BU) and cyclophosphamide (CY) without TBI
Number of subjects: 47
Study 8315433 — intervention group
Group type: EXPERIMENTAL
Intervention: Marrow treated with 4-hydroperoxycyclophosphamide (4-HC)
Number of subjects: 47
Study 8315433 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 47
Study 2423798 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 0
Study 2423798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 2423798 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 29277134 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized bandages
Number of subjects: 90
Study 29277134 — intervention group
Group type: COMPARATOR
Intervention: Unmarked bandages
Number of subjects: 90
Study 27392262 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Taping
Number of subjects: 44
Study 27392262 — intervention group
Group type: COMPARATOR
Intervention: Placebo Taping
Number of subjects: 44
Study 23560476 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel
Number of subjects: 52
Study 23560476 — intervention group
Group type: COMPARATOR
Intervention: aqueous gel
Number of subjects: 52
Study 22676644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI)
Number of subjects: 50
Study 22676644 — intervention group
Group type: COMPARATOR
Intervention: Textbook reading (No MI)
Number of subjects: 50
Study 19955879 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem program incorporated into health and physical education curriculum (32 weeks, 3 sessions of 45 minutes each week)
Number of subjects: 184
Study 19955879 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem program for girls
Number of subjects: 184
Study 19955879 — intervention group
Group type: COMPARATOR
Intervention: Regular health and physical education curriculum (no self-esteem program)
Number of subjects: 184
Study 17400686 — intervention group
Group type: EXPERIMENTAL
Intervention: Collins CPL (Ferraris Respiratory; Louisville, CO)
Number of subjects: 11
Study 17400686 — intervention group
Group type: EXPERIMENTAL
Intervention: Morgan Transflow Test PFT System (Morgan Scientific; Haverhill, MA)
Number of subjects: 11
Study 17400686 — intervention group
Group type: EXPERIMENTAL
Intervention: SensorMedics Vmax 22D (VIASYS Healthcare; Yorba Linda, CA)
Number of subjects: 11
Study 17400686 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaeger USA Masterscreen Diffusion TP (VIASYS Healthcare; Yorba Linda, CA)
Number of subjects: 11
Study 17400686 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Graphics Profiler DX System (Medical Graphics Corporation; St. Paul, MN)
Number of subjects: 11
Study 17400686 — intervention group
Group type: EXPERIMENTAL
Intervention: All instruments
Number of subjects: 11
Study 15351856 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9 genotyping prior to initiation of warfarin therapy (genotyped group)
Number of subjects: 0
Study 15351856 — intervention group
Group type: COMPARATOR
Intervention: Standard care of an anticoagulation clinic (non-genotyped group)
Number of subjects: 0
Study 11606677 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioural Rating Scale-Revised (NRS-R)
Number of subjects: 210
Study 11606677 — intervention group
Group type: COMPARATOR
Intervention: Glasgow Outcome Scale (GOS)
Number of subjects: 210
Study 11606677 — intervention group
Group type: COMPARATOR
Intervention: Disability Rating Scale (DRS)
Number of subjects: 210
Study 9145846 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg single dose)
Number of subjects: 0
Study 9145846 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin (400 mg single dose)
Number of subjects: 0
Study 7962435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at approximately 3.6 mM in Earle's medium
Number of subjects: 0
Study 7962435 — intervention group
Group type: COMPARATOR
Intervention: PTX-free Earle's medium (Control)
Number of subjects: 0
Study 7962435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 0
Study 3595697 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (preoperative administration)
Number of subjects: 95
Study 3595697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 3595697 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (postoperative administration)
Number of subjects: 95
Study 30355334 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular technique
Number of subjects: 12
Study 30355334 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel technique
Number of subjects: 12
Study 27566586 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostar antiangiogenic therapy combined with NP neoadjuvant chemotherapy
Number of subjects: 30
Study 27566586 — intervention group
Group type: COMPARATOR
Intervention: NP neoadjuvant chemotherapy alone
Number of subjects: 30
Study 25070091 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol with PA
Number of subjects: 56
Study 25070091 — intervention group
Group type: COMPARATOR
Intervention: PA redosing
Number of subjects: 56
Study 25070091 — intervention group
Group type: EXPERIMENTAL
Intervention: PA administration
Number of subjects: 56
Study 23583327 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOS (individualized therapy)
Number of subjects: 138
Study 23583327 — intervention group
Group type: COMPARATOR
Intervention: CRT (general cognitive remediation therapy)
Number of subjects: 138
Study 23583327 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOS
Number of subjects: 138
Study 23583327 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 138
Study 23583327 — intervention group
Group type: COMPARATOR
Intervention: RECOS and CRT
Number of subjects: 138
Study 20153214 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 80
Study 20153214 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 80
Study 18695455 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based multimedia health promotion program
Number of subjects: 309
Study 18695455 — intervention group
Group type: COMPARATOR
Intervention: wait-list control condition
Number of subjects: 309
Study 16873785 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (immediately premeal)
Number of subjects: 21
Study 16873785 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (15 min postmeal)
Number of subjects: 21
Study 16873785 — intervention group
Group type: COMPARATOR
Intervention: RHI (30 min premeal)
Number of subjects: 21
Study 16873785 — intervention group
Group type: COMPARATOR
Intervention: RHI (immediately premeal)
Number of subjects: 21
Study 14655784 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol foam 0.05%
Number of subjects: 32
Study 14655784 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol cream 0.05% and solution 0.05%
Number of subjects: 32
Study 10654330 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (Adiuretin-SD) (n = 32)
Number of subjects: 62
Study 10654330 — intervention group
Group type: COMPARATOR
Intervention: Sodium diclofenac (n = 30)
Number of subjects: 62
Study 9289710 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AML, CGL-BC, and CLL
Number of subjects: 45
Study 9289710 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CGL and CGL-BC
Number of subjects: 45
Study 9289710 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CLL
Number of subjects: 45
Study 9289710 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AML, CGL-BC, and CGL
Number of subjects: 45
Study 9289710 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 healthy volunteers)
Number of subjects: 45
Study 1792929 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 0
Study 1792929 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine
Number of subjects: 0
Study 1792929 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0
Study 1792929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6339963 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-A phototherapy
Number of subjects: 0
Study 6339963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30696423 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 36
Study 30696423 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 36
Study 30696423 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 36
Study 30544877 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Watermarking Filtering Scheme (RWFS)
Number of subjects: 0